Zevra Therapeutics, Inc. (ZVRA)
NASDAQ: ZVRA · Real-Time Price · USD
8.98
+0.19 (2.16%)
At close: Mar 6, 2026, 4:00 PM EST
9.05
+0.07 (0.76%)
After-hours: Mar 6, 2026, 7:59 PM EST
Zevra Therapeutics Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Zevra Therapeutics stock have an average target of 21.71, with a low estimate of 18 and a high estimate of 26. The average target predicts an increase of 141.76% from the current stock price of 8.98.
Analyst Consensus: Strong Buy
* Price targets were last updated on Nov 6, 2025.
Analyst Ratings
The average analyst rating for Zevra Therapeutics stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 4 | 4 | 4 | 4 | 4 |
| Buy | 4 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 7 | 7 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $25 → $24 | Strong Buy | Maintains | $25 → $24 | +167.26% | Nov 6, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $29 → $24 | Buy | Maintains | $29 → $24 | +167.26% | Nov 6, 2025 |
| JMP Securities | JMP Securities | Buy Maintains $19 → $18 | Buy | Maintains | $19 → $18 | +100.45% | Aug 13, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $25 → $29 | Buy | Maintains | $25 → $29 | +222.94% | Jul 10, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $26 | Strong Buy | Initiates | $26 | +189.53% | Jul 2, 2025 |
Financial Forecast
Revenue This Year
102.39M
from 23.61M
Increased by 333.64%
Revenue Next Year
147.64M
from 102.39M
Increased by 44.19%
EPS This Year
1.26
from -2.28
EPS Next Year
0.57
from 1.26
Decreased by -55.15%
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 107.3M | 176.8M | ||||
| Avg | 102.4M | 147.6M | ||||
| Low | 96.8M | 128.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 354.5% | 72.7% | ||||
| Avg | 333.6% | 44.2% | ||||
| Low | 310.1% | 25.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 1.42 | 1.12 | ||||
| Avg | 1.26 | 0.57 | ||||
| Low | 1.09 | 0.28 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | -11.0% | ||||
| Avg | - | -55.2% | ||||
| Low | - | -77.5% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.